Patent intelligence · PT
PT 2481410
NITROCATECHOL DERIVATES AS COMT INHIBITORS ADMINISTERED WITH A SPECIFIC DOSAGE REGIME
NITROCATECHOL DERIVATES AS COMT INHIBITORS ADMINISTERED WITH A SPECIFIC DOSAGE REGIME
Patent details — PT 2481410
- Jurisdiction
- PT
- Status
- granted
- Grant date
- Oct 18, 2016
- Expiration
- Oct 13, 2036
- Applicant
- BIAL-PORTELA & Cª S A [PT]
- CPC classes
- A61K 31/ 4439 A I, A61K/31198, A61K/314427, A61K/314439
Quick answer
PT 2481410 (NITROCATECHOL DERIVATES AS COMT INHIBITORS ADMINISTERED WITH A SPECIFIC DOSAGE REGIME) is held by BIAL-PORTELA & Cª S A [PT]. Status: granted. Granted Oct 18, 2016. Expires Oct 13, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL-PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4439 A I, A61K/31198, A61K/314427, A61K/314439, A61K/4506, A61K/920
More from BIAL-PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2481410?
PT 2481410 (NITROCATECHOL DERIVATES AS COMT INHIBITORS ADMINISTERED WITH A SPECIFIC DOSAGE REGIME) is held by BIAL-PORTELA & Cª S A [PT]. Status: granted. Granted Oct 18, 2016. Expires Oct 13, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns PT 2481410?
BIAL-PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does PT 2481410 expire?
Our index shows an expiration date of Oct 13, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.